Supplementary Table 1 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298820.v1

2023-01-01

Abstract:Detailed summary of CRC specimens and patient overall survival.

What problem does this paper attempt to address?

Supplementary Figure 11 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298850.v1

2023-01-01

Abstract:Analysis of immune cells between paired primary and liver metastases.
Supplementary Figure 10 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D’Apuzzo,Ganesh M. Shankar,Marwan Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298853.v1

2023-01-01

Abstract:Distribution of LA and TLS across colorectal cancer sites.
Supplementary Figure 9 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298823

2023-01-01

Abstract:Progressive maturation of TLS in CRC primary tumor.
Supplementary Figure 3 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298841

2023-01-01

Abstract:Distribution of immune cells in the cancer island and stroma of metastatic CRC TME.
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Figure 12 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298847

2023-01-01

Abstract:Clustered heatmap of relative expression of proteins (GeoMX DSP) per ROI from CRCmetastatic tumor specimens (5 tumors/metastatic site).
Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G Fakih,Peter P Lee

DOI: https://doi.org/10.1158/2767-9764.CRC-23-0212

2023-10-12

Abstract:Patients with microsatellite stable (MSS) colorectal cancer with liver metastases are resistant to immune checkpoint inhibitor (ICI) therapy, while about one-third of patients with colorectal cancer without liver metastases, particularly those with lung-only metastases, respond to ICI. We analyzed primary colorectal cancer tumors and major metastatic sites (liver, lung, peritoneal) using multiplex immunofluorescence and whole-slide spatial analyses to identify variations in immune contexture and regional localization within the tumor microenvironment. While levels of T and B cells within peritumoral regions were similar, their levels were significantly lower within the tumor core of liver and peritoneal metastases compared with lung metastases. In contrast, antigen-presenting cells (APC) and APC-T cell interactions were more abundant in all regions of lung metastases. We also identified an abundance of lymphoid aggregates throughout lung metastases, but these were present only within peritumoral regions of liver and peritoneal metastases. Larger lymphoid aggregates consistent with features of tertiary lymphoid structures were observed within or adjacent to primary tumors, but not metastatic lesions. Our findings were validated using NanoString GeoMx DSP, which further showed that liver metastases had higher expression of immune-suppressive markers, while lung metastases showed higher proinflammatory activity and T-cell activation markers. Peritoneal metastases demonstrated higher expression of cancer-associated fibroblast-related proteins and upregulated PD-1/PD-L1 signaling molecules. Our results demonstrate that functional status and spatial distribution of immune cells vary significantly across different metastatic sites. These findings suggest that metastatic site-dependent immune contexture may underlie discordant responses to ICI therapy in patients with MSS colorectal cancer. Significance: Our results demonstrate that functional status and spatial distribution of immune cells vary significantly across different metastatic sites in MSS colorectal cancer. These findings suggest that metastatic site-dependent immune contexture may underlie discordant responses to ICI therapy in patients with MSS colorectal cancer.
Supplementary Table S3 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

Yingcheng Wu,Shuaixi Yang,Jiaqiang Ma,Zechuan Chen,Guohe Song,Dongning Rao,Yifei Cheng,Siyuan Huang,Yifei Liu,Shan Jiang,Jinxia Liu,Xiaowu Huang,Xiaoying Wang,Shuangjian Qiu,Jianmin Xu,Ruibin Xi,Fan Bai,Jian Zhou,Jia Fan,Xiaoming Zhang,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.22540408

2023-01-01

Abstract:Supplementary Table S3. Differentially expressed genes between LM and CRC infiltrated MRC1+ CCL18+ macrophages & SPP1+ macrophages.
FIGURE 4 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D’Apuzzo,Ganesh M. Shankar,Marwan Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298871

2023-01-01

Abstract:Higher antigen presentation potential in lung metastases. A, Correlations of the immune cell density between histologic regions. PCC were calculated from the density of each immune cell type in different histologic regions. B, Representative images of primary and metastatic colorectal cancer tumors stained with mIF panel 4. The cancer cells, TCF1+ CD4 T cells, stem-like CD8 T cells and APCs were color coded and identified as Fig. 1C. The yellow dash lines indicate the boundaries between inner and outer invasive margin. C, Mean number of TCF1+ CD4 T cells and stem-like CD8 T cells around 10 µm radius of APCs and mean number of APCs around 10 µm radius of TCF1+ CD4 T cells and stem-like CD8 T cells. D, Paired comparison of cell density between each two organs in the different histologic regions. Statistical significance was determined by Wilcoxon signed-rank test. E, GSEA of liver and lung metastases samples from GES48468. Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were used to determine significantly modified pathways. Bars in red and blue represent, respectively, a positive and negative enrichment in the associated pathway. The x axis shows the normalized enrichment score (NES) of the analysis, and the y axis the enriched pathways. F, Heat map of top genes differentially expressed in GES48468 primary and metastatic colorectal cancer tumor samples from KEGG_ANITGENE_PROCESSING_AND_PRESENTATION pathway.
Comparative Analysis of Tumor Immune Microenvironment in Primary Tumors Vs Metastatic Tissue in Microsatellite Stable Metastatic Colorectal Cancer.

Marwan Fakih,Jian Ye,Chongkai Wang,Arya Ashok,Elizabeth Mauer,Calvin Y. Chao

DOI: https://doi.org/10.1200/jco.2023.41.4_suppl.187

IF: 45.3

2023-01-01

Journal of Clinical Oncology

Abstract:187 Background: We previously demonstrated differences in responses to checkpoint inhibitors between liver and non-liver metastases (mets) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Here, we investigate differences in tumor microenvironment (TME) and mutational landscape of primary and mCRC sites. Methods: We used the Tempus clinicogenomic database to select de-identified cases of MSS mCRC which underwent Tempus xT testing. Tempus xT is a 648-gene NGS panel that detects somatic alterations and includes RNA sequencing. Gene expression patterns of different immune cells were used to predict their relative abundance within the tumor. Analyzed tumors were divided into 4 categories based: primary tumor (colon), liver, lung, and peritoneal mets. Demographics, genomic alterations, tumor mutational burden (TMB), PD-L1 expression, and proportions of B, T (CD4+, CD8+), NK cells, and macrophages were compared between all 4 categories. Chi-squared/Fisher’s exact tests or Kruskal-Wallis tests were used to assess statistical significance. Results: Genomic profiles from 4,345 unique mCRC patients were analyzed (Primary CRC = 1734; Liver = 1825; Lung = 443; Peritoneal = 343). Median TMB and PD-L1 expressions had small differences across sites that were statistically significant. KRAS mutations were more frequent and SMAD4 mutations were less prevalent in lung mets. RNA-Seq revealed significant differences in immune cell composition. Lung mets exhibited a higher percentage of B cells and lower percentage of macrophages than liver and peritoneum (p< 0.001), similar to primary tumors. CD4+ T cells were highest in primary tumors, whereas CD8+ T cells were highest in lung mets (p < 0.001). Conclusions: The TME of lung mets has a more favorable immune composition (increased CD8+ T cells and B cells, decreased macrophages) than that of liver and peritoneal mets, suggesting that MSS mCRC to the lung may potentially be more responsive to immunotherapy.[Table: see text]
Supplementary Table S2 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

Yue Wu,Shenghong Yang,Jiaqiang Ma,Zechuan Chen,Guohe Song,D. N. Rao,Yifei Cheng,Siyuan Huang,Yifei Liu,Shan Jiang,Jinxia Liu,Xiaowu Huang,Xiaoying Wang,Shuang–Jian Qiu,Jianming Xu,Ruibin Xi,Bin Fan,Jing Zhou,Jia Fan,Xiaoming Zhang,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.22540411.v1

2023-01-01

Abstract:Supplementary Table S2. Marker genes for all immune cell subsets.
Supplementary Table S4 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

Yingcheng Wu,Shuaixi Yang,Jiaqiang Ma,Zechuan Chen,Guohe Song,Dongning Rao,Yifei Cheng,Siyuan Huang,Yifei Liu,Shan Jiang,Jinxia Liu,Xiaowu Huang,Xiaoying Wang,Shuangjian Qiu,Jianmin Xu,Ruibin Xi,Fan Bai,Jian Zhou,Jia Fan,Xiaoming Zhang,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.22540405

2023-01-01

Abstract:Supplementary Table S4. Macrophage phenotypic gene signature.
Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies

Lichun Lu,Gen‐Sheng Feng,Chih‐Hung Hsu

DOI: https://doi.org/10.4103/ejcrp.ejcrp-d-22-00033

2023-01-01

Journal of Cancer Research and Practice

Abstract:Objective: Immunotherapy with immune checkpoint inhibitors (ICIs) has become a standard of care for many malignancies. The tumor microenvironment (TME) varies across different organs and affects tumor initiation, progression, and treatment outcomes. Organ-specific differential responses to ICIs have been observed in various cancers. The underlying mechanisms warrant further investigation. Data Sources and Study Selection: We enrolled relevant clinical and preclinical studies conducted by our groups and others. Current evidence and data were reviewed and future implication was discussed. Results: In patients with advanced hepatocellular carcinoma or esophageal cancer, non-small cell lung cancer, or melanoma with liver metastases, the efficacy of ICI-based therapy was generally lower in the liver than in other organs. The mouse liver cancer study showed that myeloid-derived suppressor cells (MDSCs) might play a role in immunosuppressive TME in the liver as compared to subcutaneous tissues; targeting MDSCs enhanced anti-tumor efficacy in the liver. The metastatic colon cancer models showed that monotherapy with anti-programmed death ligand-1 (PD-L1) antibody was less effective in suppressing tumor growth in the liver than in subcutaneous tissues. Mechanistically, modulation of hepatic innate immune cells was associated with the improved response of anti-PD-L1 antibody in the liver. Conclusion: The relatively unfavorable tumor response to immunotherapy in the liver of various cancers may be attributable to the immunosuppressive hepatic TME. Future comprehensive immune profiling is required to identify key factors and mechanisms in specific organs to overcome immunosuppressive TME, particularly in the liver.
Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma

Youpei Lin,Lihua Peng,Liangqing Dong,Dongbing Liu,Jiaqiang Ma,Jian Lin,Xiaofang Chen,Penghui Lin,Guohe Song,Mao Zhang,Yuming Liu,Junhua Rao,Chen Wei,Ye Lu,Shu Zhang,Guangyu Ding,Zhenyu Peng,Haorong Lu,Xiaoying Wang,Jian Zhou,Jia Fan,Kui Wu,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.22542075.v1

2023-01-01

Abstract:Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen,Zohreh Amoozgar,Xin Liu,Shuichi Aoki,Zelong Liu,Sarah M. Shin,Aya Matsui,Alexei Hernandez,Zhangya Pu,Stefan Halvorsen,Pin-Ji Lei,Meenal Datta,Lingling Zhu,Zhiping Ruan,Lei Shi,Daniel Staiculescu,Koetsu Inoue,Lance L. Munn,Dai Fukumura,Peigen Huang,Slim Sassi,Nabeel Bardeesy,Won Jin Ho,Rakesh K. Jain,Dan G. Duda

DOI: https://doi.org/10.1158/2326-6066.25523060.v1

2024-01-01

Abstract:Supplementary Table S3: IMC panel.
Supp. Tables S16-S19 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Catherine S. Grasso,Marios Giannakis,Daniel K. Wells,Takashi Hamada,Xinmeng Jasmine Mu,Michael C. Quist,Jonathan A. Nowak,Reiko Nishihara,Zhi Rong Qian,Kentaro Inamura,Teppei Morikawa,Katsuhiko Nosho,Gabriel Abril-Rodríguez,C. E. Connolly,Helena Escuin-Ordinas,Milan S. Geybels,William M. Grady,Li Hsu,Siwen Hu‐Lieskovan,Jeroen R. Huyghe,Yeon Joo Kim,Paige Krystofinski,Mark D.M. Leiserson,Dennis Montoya,Brian B. Nadel,Matteo Pellegrini,Colin C. Pritchard,Cristina Puig-Saus,Elleanor H. Quist,Ben Raphael,Stephen J. Salipante,Daniel Sanghoon Shin,Eve Shinbrot,Brian H. Shirts,Sachet A. Shukla,Janet L. Stanford,Wei Sun,Jennifer Tsoi,Alexander Upfill‐Brown,David A. Wheeler,Catherine J. Wu,Miao Yu,Syed Hassan Ejaz Zaidi,Jesse M. Zaretsky,Stacey Gabriel,Eric S. Lander,Levi A. Garraway,Thomas J. Hudson,Charles S. Fuchs,Antoni Ribas,Shuji Ogino,Annette Peters

DOI: https://doi.org/10.1158/2159-8290.22532696

2023-01-01

Abstract:Supplementary Tables S16-S19, describing IHC results on NHS/HPFS data
Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Jiefei Han,Jianchun Duan,Hua Bai,Yuqi Wang,Rui Wan,Xin Wang,Si Chen,Yanhua Tian,Di Wang,Kailun Fei,Zhuoran Yao,Shuhang Wang,Zhimin Lu,Zhijie Wang,Jie Wang

DOI: https://doi.org/10.1158/2326-6066.22543059.v1

2023-01-01

Abstract:Univariable and multivariable analysis of progression-free survival (PFS).
Supplementary Table 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Yue Wang,Mengying Hu,Olivera J. Finn,Xiao-Song Wang

DOI: https://doi.org/10.1158/2326-6066.27602047

2024-01-01

Abstract:Supplementary Table 1. A summary of the clinical trial datasets used in this study.
Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Jie-Yi Shi,Qiang Gao,Zhi-Chao Wang,Jian Zhou,Xiao-Ying Wang,Zhi-Hui Min,Ying-Hong Shi,Guo-Ming Shi,Zhen-Bin Ding,Ai-Wu Ke,Zhi Dai,Shuang-Jian Qiu,Kang Song,Jia Fan

DOI: https://doi.org/10.1158/1078-0432.22450298

2023-01-01

Abstract:PDF file - 481K, Kaplan-Meier analysis of OS and RFS for (A) MIL-Bs and (B)penetration of MIL-Bs through tumor capsule in the validation cohort.

Supplementary Table 1 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Supplementary Figure 11 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Supplementary Figure 10 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Supplementary Figure 9 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Supplementary Figure 3 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure 12 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Supplementary Table S3 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

FIGURE 4 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Comparative Analysis of Tumor Immune Microenvironment in Primary Tumors Vs Metastatic Tissue in Microsatellite Stable Metastatic Colorectal Cancer.

Supplementary Table S2 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

Supplementary Table S4 from Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies

Supplementary Table from Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Supp. Tables S16-S19 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Supplementary Table 1 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma